Company Filing History:
Years Active: 2009
Title: Innovations by Lee Hakjoo in Cancer Treatment
Introduction
Lee Hakjoo is an accomplished inventor based in Pittsford, NY (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. His work focuses on inhibiting heregulin, a protein that plays a role in cancer cell growth.
Latest Patents
Lee Hakjoo holds a patent for "Methods for inhibiting heregulin and treating cancer." This invention discloses a method using human soluble ErbB3, specifically p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The patent details how p85-sErbB3 binds to heregulin with an affinity comparable to that of full-length ErbB3, competitively inhibiting high-affinity heregulin binding to ErbB2/ErbB3 heterodimers on the surface of breast carcinoma cells. Furthermore, it describes the use of p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, serving as a negative regulator of heregulin-stimulated signal transduction and blocking cell growth. The invention also encompasses nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods for producing the protein. This innovative approach aims to therapeutically treat human malignancies associated with heregulin-mediated cell growth, such as breast and prostate cancer.
Career Highlights
Lee Hakjoo is associated with Tumor Biology Investment Group, Inc., where he continues to advance his research in cancer biology. His work has garnered attention for its potential impact on cancer therapies.
Collaborations
One of his notable collaborators is Nita J Maihle, who is also involved in cancer research. Their partnership highlights the importance of teamwork in scientific advancements.
Conclusion
Lee Hakjoo's innovative methods for inhibiting heregulin represent a significant advancement in cancer treatment. His contributions to the field are paving the way for new therapeutic strategies against malignancies associated with heregulin-mediated cell growth.